Sutro Biopharma PTB Ratio History

Key Indicators . Ptb Ratio . Stocks . USA . 
Stock . Sutro Biopharma
STRO Stock  USD 33.33  -1.50  -4.31%   
PTB Ratio stood at -0.7423 as of December 31, 2025. This metric is price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on Sutro Biopharma's equity relative to its net asset value. Over the last 16 observed reporting periods, PTB Ratio has fluctuated significantly (CV 181.3%) across periods without a clear trajectory. Complete Financial Overview
 
PTB Ratio  
 First Reported
2010-12-31
 Previous Quarter
-0.74
 Current Value
-0.74
 Quarterly Volatility
1.36902272
Macro event markers
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes

Latest Sutro Biopharma PTB Ratio Growth Pattern

PTB Ratio10 Years Trend
High Variability
   Ptb Ratio   
       Timeline  

PTB Ratio Trend Statistics

Sutro Biopharma's PTB Ratio carries a CV of 181.3% across 10 periods, indicating elevated dispersion relative to the mean. Linear regression yields an R-squared of 0.15, pointing to a weak linear trend that explains limited variance.
Arithmetic Mean 0.76
Geometric Mean 0.45
Coefficient Of Variation 181.32
Mean Deviation 1.23
Median-0.07
Standard Deviation 1.37
Sample Variance 1.87
Range4.1453
R-Value 0.39
Mean Square Error 1.70
R-Squared 0.15
Significance 0.12
Slope 0.11
Total Sum of Squares 29.99

Sutro Biopharma PTB Ratio History

Across 10 reported periods (2017–2026), Sutro Biopharma's PTB Ratio has moved from -0.98 to -0.71.
2026 -0.71
2025 -0.74
2024 3.17
2023 1.72
2022 1.89
2021 2.72
2020 2.13
2019 2.58
2018 1.57
2017 -0.98

Correlation of PTB Ratio With Other Accounts

Cross-account correlations for Sutro Biopharma's PTB Ratio measure how closely related line items have moved together historically. Correlation does not establish cause and effect.
Click cells to compare fundamentals

Related Fundamentals

Last ReportedEnd Of Year Estimate
Price To Sales Ratio 0.96 0.91
Days Sales Outstanding 14.16 13.46
Book Value Per Share-15.59 -16.37
Free Cash Flow Yield-181.98%-173.00%

Methodology, Assumptions & Data Sources

Sutro Biopharma's PTB Ratio is charted across its full reporting history. Elevated period-to-period dispersion can signal sensitivity to input costs, demand cycles, or financing conditions. As a Biotechnology company, Sutro Biopharma's PTB Ratio should be benchmarked against sector peers for meaningful interpretation.

Sutro Biopharma data is compiled from periodic company reporting and market reference feeds and standardized for comparability. Analyst inputs may be included when coverage is available. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.

Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.